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ABSTRACT 
Background: Seasonal influenza concerns the worldwide population every year, whilst 
pandemic influenza is an unpredictable threat. Due to an important socioeconomic impact, 
mitigation measures must be specified. Governments elaborate vaccination policy based on 
scientific evidence. However, this process is, in general, not transparent.  
Objectives: To study the decision-making process related to the influenza vaccination policy, 
identifying the actors involved, the decisions made and describing the information used by 
type and level of importance.  
Methods: Six major databases were searched in seven languages, without time limit, using 
keywords related to influenza vaccination, decision-making and health policy. Titles and 
abstracts were screened according to three established criteria. Selected articles were analysed 
and compared against a checklist for context, stakeholders and evidence. 
Results: 111 articles were retrieved since the 1990s, most of them (40%) were conducted in 
the USA. The decision-making process mainly concerned vaccination strategies (53%) and 
pandemic preparedness (28%). Stakeholders were identified at an institutional, production and 
consumer level. Evidence used by policy-makers was similar (e.g. logistics of vaccines), but 
the factors influencing were different (e.g. social conditions). 
Conclusion: Considering the imminent risk of socio-economic disruption and media pressure, 
the pandemic threat needs to be integrated into an analysis of decision making processes 
regarding seasonal influenza vaccination. 
 
 
KEYWORDS: decision-making, influenza vaccination, public health policy 
 
JEL CLASSIFICATION: I18 
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INTRODUCTION 
In annual inﬂuenza epidemics, 5-15% of the world population is affected with acute 
respiratory infection. Most people with the illness recover quickly, but children, elderly and 
those with chronic medical conditions are at higher risk for complications and sometimes 
death (OECD, 2011). According to the World Health Organization (WHO) these annual 
epidemics result in 3-5 million cases of severe illness and 250-500 thousand deaths 
worldwide. In terms of costs of healthcare, lost days of work and education, and social 
disruption are between USD 1 million and USD 6 million per 100,000 inhabitants yearly in 
industrialized countries (WHO, 2009). In the case of influenza pandemic, this impact could be 
increased by a high order of magnitude (Chick et al., 2008). 
Policy-makers at all levels are usually interested in the socioeconomic impact of influenza, in 
order to better allocate resources for strategies of prevention and control, such as vaccines 
(Jefferson and Demicheli, 1998). Although vaccines could be considered effective (Germann 
et al., 2006; Osterholm et al., 2012) and cost-effective (Nichol et al., 1994), their suboptimal 
allocations can be attributed to misaligned incentives of policy-makers (Chick et al., 2008). 
Nevertheless, there is a lack of studies evaluating the decision-making process regarding the 
supply chain of vaccines and vaccination strategies during seasonal or pandemic contexts. 
This situation leads to the main question of our research: which kind of evidence do policy-
makers use when facing decisions concerning influenza? 
The objective of this literature review is to emerge studies evaluating the decision-making 
process related to the influenza vaccination policy. The secondary objectives are to identify 
the actors involved and their role in the process, to describe the information used in decision 
making for vaccination policy, to group by type of information, to classify by level of 
importance, to describe the decisions made. 
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METHODS 
 
Search definitions 
Keywords were chosen based on the terms of the Medical Subject Heading (MeSH). They 
were combined according to the main objective of this literature review: study the decision 
making process of influenza vaccination policy: 
- Influenza vaccines  
- Vaccinations AND Influenza 
- Decision support techniques OR decision making 
- Policy OR public health OR public health administration OR health policy OR public 
policy OR Management 
 
No limits of period or location delimitation were applied.  
 
Main electronic databases were use: 
- Web of Science (consists on seven multidisciplinary databases containing information 
gathered from scholarly journals, books, reports, conferences coverage in the sciences, social 
sciences, arts and humanities) 
- Google Scholar (includes most peer-reviewed online journals of Europe and America's 
largest scholarly publishers, plus scholarly books and other non-peer reviewed journals) 
- Pubmed (includes citations for biomedical articles from MEDLINE and life science journals) 
- EconLit (contains abstracts of the international economic literature and related fields: 
economy, growth, development and technological change, demography, econometrics, finance 
and money, mathematical and quantitative methods, natural resources) 
- Euronheed (network built on the foundations of two databases: 1-NHS EED: UK’s National 
Health System Economic Evaluation Database and 2-CODECS: Connaissances et Décision en 
Économie de la Santé French database of Knowledge and Decision in Health Economics; it is 
also composed by other five European databases of economic evaluation: Germany, Italy, 
Netherlands, Nordic, Spain) 
- Cochrane (collection of databases in medicine and other healthcare specialties; database of 
systematic reviews and meta-analyses, which summarize and interpret the results of medical 
research) 
References without abstracts and which full text was written in other language different from 
English, French, Spanish, German, Italian and Portuguese were excluded. 
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Specific databases such as the Centers for Disease Control and Prevention’s (CDC) reports or 
the World Health Organization (WHO) Bulletins were also searched. 
 
Criteria for inclusion and exclusion 
The articles retrieved had titles and abstracts screening according to criteria of inclusion and 
exclusion established. 
 
Inclusion criteria 
- Presence of macro 1 level decision-making (at local, regional, national or international 
levels) regarding influenza vaccination programs (target groups, reimbursement…) 
and vaccines (formulation, stockpile, distribution, production, management…), 
- Description of the actors involved in this decision, 
- Description of the information used during the decision making process assessed. 
 
Exclusion criteria 
- Decisions made in meso or micro2 levels only, such as in hospitals, clinics or medical 
offices (relation between physicians and patients), 
- Assessments of the willingness of people (general population, health care 
professionals, parents of children…) to get vaccinated or to accept recommendations 
or requirements about getting vaccinated, 
- Modeling studies concerning past vaccination strategies adopted, or proposition of 
new strategies (optimal vaccination strategies), 
- Economic evaluations (cost-benefit, cost-effectiveness, cost-of-illness, economic 
burden…) about vaccine efficacy/effectiveness and vaccination rate. 
 
Checklist for full text reading 
Articles selected to full text reading were checked according to the following list: 
- What is the current context (influenza pandemic or seasonal, health system, politics, 
socio-demographic, economics)? 
- Which decisions are under discussion (vaccination strategies and vaccines)? 
                                                      
1 From an organization perspective, the macro level refers to the actors and institutions within which the general 
organizational, regulatory frameworks and public health interventions of the broad health system are established and 
delivered, beyond national borders or not. 
2 From an organization perspective, the meso level refers to medium-sized units of service provision such as primary 
healthcare units or hospitals, and the micro level refers to interactions between individual patients and healthcare 
professionals. 
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- who are the stakeholders (agencies providing recommendations about vaccines 
formulation and vaccination practices, policy-makers, manufacturers, healthcare 
professionals, patients -associations of high risk groups, anti-vaccine leagues-)? 
- Which information influence decision-making (clinical evidence, burden of disease 
and epidemiological studies, economic evaluations)? 
- Is there other factors influencing in decisions (experts opinions, pressure of groups 
target for vaccination, the media)? 
- What is the relation between different stakeholders? 
- What is decided? 
 
Aiming to facilitate the analysis we classified each of the points highlighted in the checklist. 
This classification is based in the common characteristics of stakeholders and the impact of 
the information in the decision made.  
 
 
RESULTS 
 
Articles inclusion 
Electronic databases search retrieved 4743 references. Based on the titles and abstracts, we 
excluded: 465 articles that did not have an abstract, 348 repeat texts and 3588 that did not 
meet the inclusion criteria. 342 articles were selected for full text reading. After a detailed 
reading of those, 231 (68%) were excluded because they actually didn’t match the inclusion 
criteria. Finally, we consider for analysis 111 articles (Annex 1).  
 
Most of the articles excluded concerned local decision-making process (meso/micro level). 
They were mainly related to the personal choice of being vaccinated, especially target people 
such as children, elderly, immunosuppressed, patients with chronic diseases and healthcare 
professionals. Other articles excluded concerned decisions related to the influenza vaccines: 
composition, virus strains selection (virology and immunology assays), vaccine 
efficacy/effectiveness (randomized clinical trial, economic evaluations and modeling), 
adverse events of vaccines and vaccination rates. Decisions regarding solely antivirals policy 
were also excluded.  
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Period of publication 
Publication of articles ranged from year 1994 to 2012. Peaks of publication happened in the 
years with a remarkable event, such as a pandemic, vaccine disruption and ethical issues. Fifty 
seven percent (n=63) of the articles included were published in the last three years (from 2009 
to 2012). The possible reason is the pandemic human influenza (H1N1pdm09) happened in 
the year of 2009. Twenty five percent (n=28) of the articles were published in 2005 and 2006. 
In this case, a shortage of vaccine supply in 2005 seasonal influenza in the US was in the 
spotlights together with ethical issues of equitable access, distribution and allocation of 
existing vaccine resources. Four publications related to epizootic pandemic influenza H5N1 
of 2003 were included from 2003 and 2004  
 
Location 
The United States was the most common local chosen by authors in local, state or federal 
levels3 (n=44, 40%). The comparison between vaccination policies in the US and European 
countries, Canada, or Latin America was the object of other 7 studies.  
Eight studies conducted in Canada mostly evaluated pandemic preparedness plan and 
compared national influenza vaccine strategies to other countries around the world. 
Twenty six percent of the studies (n=29) did not focus on a particular location for the 
analysis, but made a global comparison about vaccination policies and pandemic preparedness 
plan. European countries (France, Germany, Italy, Israel, Netherlands) were selected for 
twelve studies and one comparison with Canada and US. 
Representing the east side of the globe, Australia (n=7), India (n=2) and Hong Kong (n=1) 
evaluated their vaccination strategy and pandemic preparedness plan. Table 1 details the 
location where the studies were conducted. 
 
  
                                                      
3 The US government is responsible for the buying and distribution of influenza vaccines in the US. This work is largely 
carried out by the Centers for Disease Control and Prevention. As a result, there are many US publications in the public 
domain regarding this issue which appear every year. For example, the CDC gives a regular update on vaccine supplies each 
winter. However, this is not comparable to other countries where other procedures are at work and supply is often left more 
to the private market. 
. 
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Table 1: Location where studies were conducted 
Location Decisions made Nb of 
studies 
# 
Australia Vaccine prioritization, purchasing 
Pandemic preparedness plan 
7 25, 26, 37, 48, 78, 85, 132 
Canada Vaccine production, prioritization, 
purchasing 
Pandemic preparedness plan 
6 11, 69, 97, 102, 108, 125 
Canada and others 
(Australia, France, Mexico, 
Sweden, US, UK) 
Vaccination strategy 
Pandemic preparedness plan 
2 41, 131 
China/ Hong Kong Pandemic preparedness plan 1 70 
EU Vaccine virus selection, 
prioritization 
Vaccination strategy 
Pandemic preparedness plan 
8 2, 31, 34, 59, 74, 100, 117 
EU, Canada, US Vaccine production, prioritization, 
distribution 
1 33 
France Vaccination strategy 1 38 
Germany Pandemic preparedness plan 1 115 
India Pandemic preparedness plan 2 42, 66 
Israel Vaccine purchasing 1 14 
Italy Vaccine prioritization 1 23 
Netherlands Pandemic preparedness plan 1 109 
USA Vaccine virus selection, 
development, production, 
prioritization, purchasing, supply 
Vaccination strategy 
Pandemic preparedness plan 
51 1, 8, 12, 15, 16, 18, 19, 20, 
22, 30, 36, 39, 45, 46, 47, 49, 
50, 51, 52, 55, 57, 58, 61, 63, 
67, 68, 72, 73, 76, 77, 80, 82, 
83, 84, 86, 87, 88, 89, 91, 98, 
99, 113, 114, 121 
USA and others  
(Canada, EU, UK, Latin 
America) 
Vaccination strategy 
Pandemic preparedness plan 
7 93, 103, 54, 101, 44, 104, 124 
Global  
(no country specified) 
Vaccine virus selection, 
development, production, 
prioritization, purchasing, supply 
Pandemic preparedness plan 
29 9, 90, 92, 94, 110, 119, 3, 4, 
5, 6, 7, 10, 13, 17, 24, 28, 29, 
32, 53, 56, 60, 62, 64, 71, 75, 
81, 96, 105, 107 
 
Current context 
In order to classify the articles found, we use the assumptions driven by the virus-centric 
thinking which leads to dichotomizing influenza into “pandemic” and “seasonal”, according 
to the genetic mutations of the flu virus (Doshi, 2011). On this basis, we found that 81 articles 
were related to pandemic and 24 to seasonal flu. Some articles (n=6) discussed how seasonal 
influenza surveillance systems could be used in pandemic situations, giving emphasis on both 
seasonal and pandemic contexts. Half of the 111 articles included, target the preparedness 
plan for influenza pandemic, before, during and after the occurrence of a pandemic. Ancient 
and recent pandemics (1918, 1957, 1968, 2009) are taken as examples of what has been 
learned and what was improved meanwhile. 
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Stakeholders  
The noun “stakeholder” receives different definitions according to the environment in where 
it is used. In our research, we adopted the business concept retrieved at the Collins Dictionary 
online (Collins, 2012) which defines stakeholder as: “a person, group, organization, member 
or system that affects or can be affected by a project or event”. 
Stakeholder cans also be used as an adjective that matches with our study: “of or relating to 
policies intended to allow people to participate in and benefit from decisions made by 
enterprises which they have a stake”. Stakeholders, related to influenza vaccination policy, 
who participate in and benefit from decisions made by health organizations which they have a 
stake were identified and classified in the following groups: 
 
- Institutional level: 
o International organizations: WHO, World Bank, 
Regional departments: EuroWHO, Pan American Health 
Organization (PAHO), (European Center for Disease Prevention 
and Control (ECDC), 
o National institutes: Advisory Committee on Immunization Practices 
(ACIP), Food and Drug Administration (FDA), CDC, Australian Health 
Protection Committee (AHCPR), 
o Governments (Ministry of Health, Health department), 
National/federal, Province/state/territory, local, 
 
- Production level (market forces): 
o Manufacturers of vaccines, 
o Healthcare providers: insurance companies, clinics, hospitals, 
o Healthcare workers, professionals: nurses, pharmacists, physicians, 
 
- Consumers level: 
o General public. 
 
Information influencing decisions and other factors of impact 
Main information and factors influencing decisions were identified in the articles selected. 
Fourteen categories were established and ranked in Table 2 according to its impact on the 
decision. 
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Table 2: Main information and factors influencing the decision making process regarding 
influenza vaccination policy 
Main information, 
number of articles 
related 
Information detailed # 
Logistics of vaccines 
n=46 
 
Virus selection/composition 
Development 
Production/manufacturing 
Industrial capacity 
Prioritization/rationing 
Purchase/order/demand 
Distribution/supply/allocation 
Delivery  
Social acceptance 
Recommendation 
Mandatory 
Mass campaign 
Programmatic administration 
2, 4, 6, 8, 9, 10, 11, 13, 14, 16, 17, 20, 30, 33, 
38, 39, 45, 50, 51, 53, 57, 58, 62, 63, 64, 68, 
71, 72, 73, 74, 76, 77, 81, 83, 89, 91, 94, 97, 
98, 103, 105, 107, 108, 114, 115, 125 
Influenza surveillance 
data  
n=41 
 
Flu activity 
Transmissibility 
Geographic distribution 
Time course of pandemic 
6, 7, 8, 11, 13, 17, 20, 22, 23, 24, 26, 29, 32, 
36, 37, 44, 51, 55, 56, 63, 66, 70, 71, 72, 73, 
76, 82, 83, 84, 86, 90, 93, 97, 98, 107, 109, 
113, 114, 115, 119, 126 
Vaccines scientific 
studies 
n=37 
 
Randomized clinical trials: vaccine 
efficacy 
effectiveness 
safety 
clinical evidence, scientific, 
observational studies 
immunization 
1, 4, 11, 13, 14, 28, 30, 31, 32, 33, 34, 36, 37, 
38, 44, 45, 46, 53, 56, 58, 59, 61, 67, 69, 73, 
75, 78, 81, 85, 86, 93, 99, 100, 101, 102, 104, 
105 
Local status, social 
conditions 
n=26 
 
Logistics for pandemic response 
Education 
Politics (political willingness) 
Economy 
Media  
Transparency  
18, 28, 39, 41, 42, 44, 45, 50, 53, 54, 61, 80, 
85, 87, 88, 89, 90, 91, 97, 99, 107, 113, 115, 
117, 121, 125 
Epidemiology 
n=25 
 
Morbidity 
Mortality 
Severity 
3, 8, 10, 11, 13, 15, 18, 23, 24, 30, 33, 36, 41, 
49, 54, 56, 71, 73, 74, 81, 84, 92, 109, 115, 132 
Ethics 
n=24 
 
Professional judgments 
Cultural requirements 
Willingness to be vaccinated 
Legal/juridical approaches 
Philosophy grounds  
5, 11, 16, 19, 42, 46, 48, 51, 58, 67, 69, 70, 76, 
78, 81, 87, 89, 92, 93, 99, 101, 102, 103, 121 
Guidelines 
n=24 
 
Reviews, reports, records, 
publications, website docs 
Protocols, checklist 
Recommendation 
3, 19, 25, 26, 30, 31, 34, 41, 47, 50, 54, 55, 58, 
66, 68, 75, 85, 97, 102, 110, 111, 112, 124, 131 
Virological diagnosis 
n=19 
 
Serological 
Antigenic strains 
Laboratory capacity 
6, 13, 23, 28, 29, 38, 44, 53, 57, 64, 66, 71, 93, 
96, 100, 104, 114, 119, 126 
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Main information, 
number of articles 
related 
Information detailed # 
Financial resources 
n=18 
 
Funding 
Budget 
10, 14, 25, 29, 49, 51, 62, 64, 74, 77, 97, 98, 
100, 101, 102, 104, 114, 119 
Registries 
n=16 
 
Past pandemic information 
History 
Lessons learned 
8, 11, 12, 13, 15, 26, 60, 62, 63, 68, 86, 93, 99, 
108, 110, 132 
Models 
n=14 
 
Mathematical 
Decision policy analysis 
 
6, 7, 11, 12, 15, 16, 20, 24, 38, 51, 52, 96, 108, 
109 
Experts advices 
n=13 
Advisory groups 
Scientific committees 
2, 5, 14, 30, 47, 55, 58, 60, 61, 77, 99, 109, 121 
Economic studies 
n=13 
 
Burden of influenza 
Cost-benefit analysis 
Cost-effectiveness analysis 
Risk analysis  
Uncertainty 
9, 11, 15, 33, 54, 59, 81, 93, 100, 105, 109, 
117, 121 
Demographics 
n=5 
Population size and age 19, 68, 91, 108, 125 
 
Decisions made 
Two main categories of decisions were established: (1) vaccination strategy and (2) pandemic 
preparedness plan. Vaccination strategy is analyzed in both pandemic and seasonal contexts. 
Although vaccination strategy can be part of a pandemic preparedness plan, it is here analyzed 
separately (Annex 2). 
1) Vaccine strategy (n=70, 53%)4 
the steps of a vaccination strategy do not depend on the context (pandemic or seasonal), 
and it corresponds to the pharmaceutical cycle of the vaccine, from its conception, through 
logistics of distribution until consumption. Decisions are specific to each stage of this 
cycle and regards the main choices described below:  
a) Virus selection, composition or formulation of the vaccine: 
influenza strains to include, trivalent vs. quadrivalent, pandemic… 
b) Development of the biological product (requires R&D5) 
use of adjuvants, eggs vs. cell culture, age restrictions… 
                                                      
4 See annex 2. 
5 The term R&D or research and development refers to a specific group responsible for develop new products; 
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c) Production, manufacturing (requires approval by regulatory institutes) 
quantity to produce, consider reimbursement 
d) Purchase, ordering 
amount to purchase, prioritization of groups target (age, medical condition…), 
allocation of resources, mandatory vaccination (healthcare workers, military…) 
e) Distribution from manufacturer to the purchaser or from centralized to decentralized 
levels 
logistics of delivery, transportation of thermosensitive biologicals 
f) Vaccine intake 
incitation for vaccination (universal free vaccine, reimbursement, mandate), 
allocation of healthcare expenditures.  
This final step will not be analyzed once it concerns a lower level of decision (patient 
level, social acceptance of getting vaccines), and we are interested in higher levels 
(policy level).  
 
2) Pandemic Preparedness Plan (n=37, 28%)6 
Generally, when policy makers elaborate an influenza pandemic preparedness plan, a 
vaccination strategy is included as one of the measures for containing pandemic virus spread. 
Other measures for control are also included in the plan, such as social distance and isolation 
(closing schools, quarantine), disinfection, antivirals promotion. Although these measures are 
usually adopted together with a vaccination strategy, we are only focusing on the latter. The 
most important difference between vaccination strategies during seasonal or pandemic context 
is the situation of risk faced by policy makers. Concepts of uncertainty, risk management and 
emergency actions are usually adopted. 
 
Information used in decisions made in the contexts of seasonal or pandemic influenza is 
similar, but the factors influencing were very different. A routine situation of annual influenza 
policy in the case of a seasonal flu becomes an uncertainty context of risk management when 
a pandemic is declared. 
 
 
 
                                                      
6 See annex 2. 
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DISCUSSION  
This literature review identified the contexts where influenza policy is done and the 
information used. Most of the publications referred to decisions made in the context of 
pandemic influenza, due to the imminent risk of socio-economic disruption and media 
pressure. The other articles analyze if measures adopted for seasonal influenza can be used in 
case of pandemic. Main factors influencing or information used when elaborating plans for 
control measures against influenza seasonal or pandemic are described below. 
 
Population target for vaccination 
The first issue to be considered when planning for a seasonal or pandemic influenza is the 
target population for vaccination. This is based on assumptions of the group that might get 
most benefit from vaccination. Studies assessing vaccine effectiveness, economic evaluations, 
type of influenza epidemiology (morbi-mortality) and data about vaccination rates are useful 
to justify choices made (Lee et al., 2012; Lipsitch et al., 2011). 
 
Vaccines formulation and production 
WHO recommends annually the virus composition of seasonal influenza vaccine for both 
northern and southern hemispheres. These recommendations are based on surveillance data 
from sentinel influenza networks worldwide and antigenic virological information provided 
during the whole year by the National Influenza Centres responsible for virus identification, 
subtyping and characterization. For pandemic vaccines, once the virus is isolated, 
recommendations about the antigenic characteristics are provided. Manufacturers have then 
some months before the winter season, where influenza is epidemic, to make available a 
sufficient amount of vaccines for supplying the world demand. Commercial interest 
associated with studies of vaccine effectiveness in different age groups and antigenic match 
(between the circulating virus and the current vaccine composition) encourage manufacturers 
to promote new types of vaccines. These vaccines can present different formulations from the 
ones recommended by WHO, target a specific age group, or can be available by nasal 
administration, for instance (Kamradt-Scott, 2012; Yaesoubi and Cohen, 2011). 
 
Communication 
Communication between stakeholders involved in the decision making process was seen to be 
very important for the success of the vaccination policy. Collaboration between different 
levels of governance (federal, state/regional, local), health institutes, experts and 
14 
 
manufacturers enable robustness of information produced and evidence used in the policy. 
Transparency when involving health care professionals and patients in the process of policy 
elaboration is essential to guarantee compliance. The media should be seen as an alliance, so 
information given must also be transparent and retrieved from confident sources 
(Gazmararian et al., 2006; Ringel et al., 2009). 
 
Ethics 
Policy implementation is certainly enhanced when decision makers are perceived to act in a 
responsible and ethical manner. Healthcare professionals have rights and obligations that must 
be taken into account, but during a pandemic the individual rights are questionable in the 
benefit of the society. This polemic statement is discussed in some of the articles included, 
and contradictory opinions are given (Dupras and Williams-Jones, 2012; Monto et al., 2011). 
 
Implications 
This literature review did not retrieve any publication conducted in France that evaluated the 
decision process regarding influenza policy with policy makers involved. Few studies 
conducted in the US and Canada reported findings obtained after surveys or workshops 
promoted with the objective of improving the seasonal influenza plan and the preparedness 
plan for pandemic influenza. According to these studies, feedbacks of the workshops were 
positive and changes were successfully approved and adopted by local vaccination policies. 
However, studies surveying patients and healthcare professional against vaccination were not 
found (Doxtator et al., 2004; Neudorf et al., 2003; Oxford et al., 2005; Stroud et al., 2011). 
 
 
CONCLUSION 
Articles included in this literature review were retrieved since the 1990s until 2012. Most of 
them were conducted in the North America (59%) and Europe (11%). Stakeholders were 
identified as institutional, production and consumers levels. Decisions were made in both 
seasonal and pandemic context regarding several levels of the vaccine lifecycle chain. Each 
step of this chain required specific decisions, which were based on similar evidence in 
different countries. However, no standard process among locations was observed. External 
factors, such as the health system, economic context and the resources allocated influenced on 
the decision making process. 
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Further studies based on this literature review will consist on the elaboration of questionnaires 
and a semi-structured interview. These could be applied to the stakeholders involved in the 
vaccination policy here identified, for example by comparing different locations or levels of 
decisions, and groups pro and against vaccination. Evidences and information used may be 
stated to the respondents, for verifying the existence of standard procedures or justifying such 
a position regarding vaccination. Local peculiarities of French health system, the political and 
economic context and in case of a pandemic or not must be taken into account. After 
validation and data collection in France a second phase is planned. 
Questionnaires and the interview could be adapted to stakeholders located in the Netherlands. 
Local details would be considered. Data collected in France would be compared with Dutch 
data. Vaccination policies and the opinions of different stakeholders within and between 
countries would be analyzed. Future findings could be used as another source of information 
for changes and improvement of the existing vaccination policy in both countries. 
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Annex 1 – List of articles included by date of publication 
 
# Authors Period of publica-ion Country Context 
1 Phillips 2012 USA seasonal flu 
2 Mereckiene 2012 EU pandemic flu 
3 Lee 2012 not specified pandemic flu 
4 Kamradt-Scott  2012 not specified pandemic flu 
5 Dupras 2012 not specified pandemic flu 
6 Ampofo 2012 not specified seasonal flu 
7 Yaesoubi 2011 not specified pandemic flu 
8 Stroud 2011 USA pandemic flu 
9 Ng 2011 many in the world both 
10 Monto 2011 not specified pandemic flu 
11 Moghadas 2011 Canada pandemic flu 
12 Maciejewski 2011 USA pandemic flu 
13 Lipsitch 2011 not specified pandemic flu 
14 Levine 2011 Israel pandemic flu 
15 Lee 2011 USA pandemic flu 
16 Lee 2011 USA pandemic flu 
17 Kamradt-Scott  2011 not specified pandemic flu 
18 Hollingsworth 2011 USA pandemic flu 
19 French 2011 USA pandemic flu 
20 Chao 2011 USA pandemic flu 
22 Burke 2011 USA pandemic flu 
23 Ajelli 2011 Italy pandemic flu 
24 Abellin 2011 not specified pandemic flu 
131 Lam 2011 Canada and others (Australia, Mexico, US, 
UK) 
pandemic flu 
132 Kelly 2011 Australia pandemic flu 
25 Weeramantheri 2010 Australia pandemic flu 
26 Spokes 2010 Australia pandemic flu 
28 Rosner 2010 not specified seasonal flu 
29 Richard 2010 not specified seasonal flu 
30 Rambhia 2010 USA pandemic flu 
31 Nicoll 2010 EU pandemic flu 
32 Morens 2010 not specified pandemic flu 
33 Monto 2010 EU, Canada, USA seasonal flu 
34 Mereckiene 2010 EU seasonal flu 
36 Lee 2010 USA pandemic flu 
37 Leask 2010 Australia seasonal flu 
38 Labro 2010 France both 
39 Kuehnert 2010 USA pandemic flu 
41 Kendal 2010 Canada and others (Australia, England, 
France, Sweden, US) 
pandemic flu 
42 Kakkar 2010 India pandemic flu 
44 Dehner 2010 USA, Europe pandemic flu 
45 Cho 2010 USA seasonal flu 
46 Bernstein 2010 USA seasonal flu 
47 Berman 2010 USA seasonal flu 
48 Bennett 2010 Australia pandemic flu 
49 Alenzi 2010 USA pandemic flu 
50 Zigmond 2009 USA pandemic flu 
51 Schwartz 2009 USA pandemic flu 
52 Savoia 2009 USA pandemic flu 
53 Sahni 2009 not specified pandemic flu 
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# Authors Period of publica-ion Country Context 
54 Ropero-Alvarez 2009 USA, Canada and Latin America seasonal flu 
55 Ringel 2009 USA both 
56 O'Neil 2009 not specified pandemic flu 
57 Mazanec 2009 USA pandemic flu 
58 Kinlaw 2009 USA pandemic flu 
59 Johansen 2009 EU pandemic flu 
60 Hollenbeck 2009 not specified pandemic flu 
61 Gallaher 2009 USA pandemic flu 
62 Friede 2009 not specified pandemic flu 
63 French 2009 USA pandemic flu 
64 Flyborg 2009 not specified pandemic flu 
66 Chawla 2009 India pandemic flu 
67 Barnett 2009 USA pandemic flu 
68 Orenstein 2008 USA both 
69 Mah 2008 Canada seasonal flu 
70 Lam 2008 China pandemic flu 
71 Jennings 2008 not specified pandemic flu 
72 Gotham 2008 USA pandemic flu 
73 Fineberg 2008 USA pandemic flu 
74 Esposito 2008 EU seasonal flu 
75 Dutta 2008 not specified pandemic flu 
76 Wynia 2006 USA pandemic flu 
77 Whitley 2006 USA pandemic flu 
78 Torda 2006 Australia pandemic flu 
80 Sencer 2006 USA pandemic flu 
81 Schuklenk 2006 not specified pandemic flu 
82 Roddy 2006 USA seasonal flu 
83 Ransom 2006 USA pandemic flu 
84 Lewis 2006 USA pandemic flu 
85 Letts 2006 Australia pandemic flu 
86 Krause 2006 USA pandemic flu 
87 Kayman 2006 USA pandemic flu 
88 Iton 2006 USA both 
89 Hodge 2006 USA pandemic flu 
90 Gronvall 2006 many in the world pandemic flu 
91 Gazmararian 2006 USA seasonal flu 
92 Garcia-Garcia 2006 many in the world both 
93 Ferguson 2006 USA UK pandemic flu 
94 Fedson 2006 many in the world seasonal flu 
96 Wu 2006 not specified seasonal flu 
97 Tam 2005 Canada pandemic flu 
98 Seiguer 2005 USA seasonal flu 
99 Schoch-Spana 2005 USA seasonal flu 
100 Oxford 2005 EU, others pandemic flu 
101 Kotalik 2005 USA, Canada, UK pandemic flu 
102 Kort 2005 Canada pandemic flu 
103 Hadler 2005 USA, Canada pandemic flu 
104 Fedson 2005 USA, Europe pandemic flu 
105 Daems 2005 not specified pandemic flu 
107 Gostin 2004 not specified pandemic flu 
108 Doxtator 2004 Canada pandemic flu 
109 Van Genugten 2003 Netherlands pandemic flu 
110 Van Essen 2003 many in the world seasonal flu 
113 Strikas 2002 USA pandemic flu 
114 Gensheimer 2002 USA pandemic flu 
115 Fock 2002 Germany pandemic flu 
117 McDaid 2001 EU seasonal flu 
119 Wunderli 1997 many in the world seasonal flu 
121 Hinman 1997 USA seasonal flu 
124 Nicholson 1995 USA, Europe seasonal flu 
125 Tamblyn 1994 Canada pandemic flu 
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Annex 2 – Categories of decisions established, main actors and information used 
 
Decision Actors Current 
Context 
Information 
influencing 
Other factors 
influencing 
decisions 
# 
VACCINE 
STRATEGY 
 
Vaccine virus 
selection and 
composition 
(adjuvants...) 
WHO, GIRS,  
manufacturers, 
health authorities, 
virological labs, 
veterinarian 
 
Seasonal -antigenic 
history  of 
strains, 
frequency and 
type 
-pathogenicity of 
variants 
-serological 
studies 
-virus sharing 
between countries 
-influenza 
surveillance 
6, 96, 45, 119, 
29 
= = Pandemic -antigenic 
characteristics of 
pandemic virus 
-logistics 
-financial 
64, 59 
VACCINE 
STRATEGY 
Vaccine 
development 
Health  
authorities, 
manufacturers, 
EMEA, FDA 
Seasonal x * 
 
*no “seasonal” 
articles 
regarding 
vaccine 
development 
x x 
= = Pandemic -influenza 
activity  
-severity 
-virological 
information 
-economic 
studies 
-influenza 
surveillance 
- logistics 
- regulatory 
agencies approval 
-financial 
22, 17, 64, 56, 
83, 105, 90, 15, 
104 
VACCINE 
STRATEGY 
Vaccine 
production 
manufacturing 
CDC, 
manufacturers, 
health authorities 
Seasonal -vaccine clinical 
studies 
-demographics 
-logisitics 
- authorities 
recommendations 
 
45, 39, 33 
= = Pandemic -standard 
operating 
procedures 
-batch process 
records 
 
-historical records 
-influenza 
surveillance 
-financial  
-skilled personnel 
-timeline of 
pandemics 
-validation 
procedures 
62, 68-both, 
90, 86, 105, 
125 
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Decision Actors Current 
Context 
Information 
influencing 
Other factors 
influencing 
decisions 
# 
VACCINE 
STRATEGY 
Vaccine 
prioritization, 
rationing  
(definition of 
priority groups) 
Mandatory 
vaccination 
(HCW) 
ECDC, EMA, 
WHO, HSC, MS, 
healthcare 
providers 
Seasonal -epidemiology 
data 
-vaccine clinical 
studies 
-ethics, 
philosophy and 
cultural grounds 
 
-logistics 
-economic studies 
-political 
willingness 
-local status (public 
and stakeholders 
opinion) 
1, 33, 117, 46, 
37, 69, 9-both, 
99, 124 
= = Pandemic -epidemiology 
data 
-vaccine clinical 
studies 
-models 
-ethics, law, 
jurisdictions 
-severity 
-demographics 
of pandemics 
-virological data 
 
-logistics 
-influenza 
surveillance 
-authorities 
recommendations 
-experts 
-financial 
-local status (public 
and stakeholders 
opinion) 
-skilled personnel 
 
3, 4, 51, 71, 89, 
102, 114, 125, 
53, 87, 23, 76 
VACCINE 
STRATEGY 
Vaccine 
purchasing, 
ordering 
WHO, SAGE, 
health authorities, 
manufacturers,  
Seasonal -demographics 
-history of 
previous years 
demand 
 
-authorities 
recommendations 
82, 68 -both 
= = Pandemic -prescription pad 
orders 
-severity 
-epidemiology 
-economic 
studies 
-vaccine clinical 
studies 
-ethics, law 
-demographics 
-influenza 
surveillance 
-local status (public 
and stakeholders 
opinion) 
-experts 
-regulatory 
approval 
-financial 
-timeline of 
pandemics 
-guidelines 
72, 14, 11, 10, 
25, 74, 89, 125 
VACCINE 
STRATEGY 
Vaccine 
distribution, 
supply, allocation 
WHO, health 
authorities, 
manufacturers, 
healthcare 
providers 
Seasonal -historical 
records of 
purchase 
-logistics 
-epidemiology 
-vaccine clinical 
studies 
-local status (public 
and stakeholders 
opinion) 
-financial 
-economic studies 
45, 98, 33, 94 
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Decision Actors Current 
Context 
Information 
influencing 
Other factors 
influencing 
decisions 
# 
= = Pandemic -vaccine clinical 
studies 
-epidemiology 
-models 
-ethics, law 
(willingness to 
be vaccinated) 
-influenza 
surveillance 
-logistics 
-economic studies 
-historical records 
-authorities 
recommendations 
-local status (public 
and stakeholders 
opinion) 
-guidelines 
15, 16, 24,  51, 
83,  100, 89, 
87, 83, 105, 
103, 100, 18 
VACCINE 
STRATEGY 
Vaccination 
policy 
implementation or 
management 
WHO, ECDC, 
health authorities, 
healthcare 
providers, 
virological labs, 
veterinarian 
Seasonal -vaccine clinical 
studies 
-epidemiology 
-economic studies 
-logistics 
33, 47, 38-
both, 34, 54, 
110, 28, 88, 91, 
121 
= 
(mass vaccination 
campaign) 
= Pandemic -vaccine clinical 
studies 
-influenza 
surveillance 
-severity 
-epidemiology 
-historical records 
-experts 
-local status (public 
and stakeholders 
opinion) 
-financial 
-models 
2, 8, 22, 32, 86, 
51, 44, 41, 36, 
30, 73, 15, 80, 
97 
Pandemic 
Preparedness Plan 
 Pandemic   5, 7, 12, 13, 19, 
20, 26, 31, 42, 
48, 49, 50, 52, 
55, 57, 58, 60, 
61, 63, 66, 67, 
70, 75, 77, 78, 
81, 84, 85, 92, 
93, 101, 107, 
108, 109, 113, 
115, 131, 132 
 
 
 
